PMC:7047369 / 9053-9146
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 115 | 48-53 | Species | denotes | human | Tax:9606 |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T145 | 30-44 | BV_15 | denotes | immunogenicity |
| T144 | 48-53 | SP_6;NCBITaxon:9606 | denotes | human |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T57 | 48-53 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T66 | 0-93 | Sentence | denotes | Phase 1 trials for safety and immunogenicity in human populations are likely within 3 months. |